American Made Pharmaceuticals Act of 2022
Latest action · Apr 6, 2022 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 5, 2022
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
American Made Pharmaceuticals Act of 2022
This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).
The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.
Cosponsors 1
Members who signed on, in the order they did. All signed on Apr 5, 2022.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-OK | Markwayne Mullin | Original | Apr 5, 2022 |
Committees 2
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Apr 5, 2022 |
| Health Subcommittee | Referred Apr 6, 2022 | |
| House | Ways and Means Committee | Referred Apr 5, 2022 |
Actions 3
Everything that happened, newest first.
- Apr 6, 2022Referred to the Subcommittee on Health.
- Apr 5, 2022Introduced in House
- Apr 5, 2022Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 168, no. 60, April 5, 2022, page H4191.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 3991 | American Made Pharmaceuticals Act of 2022 | Identical bill | Apr 5, 2022 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.
- Short Title(s) as Introduced
- American Made Pharmaceuticals Act of 2022
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Buy American requirements
- Child health
- Congressional oversight
- Drug therapy
- Emergency medical services and trauma care
- Health
- Health care costs and insurance
- Health technology, devices, supplies
- Infectious and parasitic diseases
- Manufacturing
- Medicaid
- Medicare
- Poverty and welfare assistance
- Prescription drugs
- Public contracts and procurement
Text 1
Each version as it was printed, newest first.
- Apr 5, 2022Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
